Clinical Trials Browser

Medulloblastoma × Nivolumab × Clear all

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Phase 1 Withdrawn

CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT03173950 2025-06-29

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Phase 2 Completed

133 enrolled

CNS

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningioma, Pinealoma, Spinal Cord Neoplasms, Choroid Plexus Neoplasms

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

Clinical Trials

PRiME II

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

PIVOT IO 020